Theravance Biopharma, Inc.
TBPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $460 | $622 | $826 | $768 |
| - Cash | $38 | $40 | $298 | $90 |
| + Debt | $50 | $49 | $74 | $652 |
| Enterprise Value | $472 | $631 | $602 | $1,330 |
| Revenue | $64 | $57 | $51 | $55 |
| % Growth | 12.1% | 11.8% | -7.2% | – |
| Gross Profit | $64 | $17 | -$12 | -$138 |
| % Margin | 100% | 29.3% | -23.5% | -250.1% |
| EBITDA | -$38 | -$52 | -$76 | -$233 |
| % Margin | -59.7% | -89.9% | -148.2% | -420.9% |
| Net Income | -$56 | -$55 | $872 | -$199 |
| % Margin | -87.6% | -96.1% | 1,698.5% | -360.6% |
| EPS Diluted | -1.15 | -1 | -1.26 | -2.87 |
| % Growth | -15% | 20.6% | 56.1% | – |
| Operating Cash Flow | -$12 | -$27 | -$187 | -$208 |
| Capital Expenditures | -$0 | -$2 | -$1 | -$3 |
| Free Cash Flow | -$12 | -$29 | -$188 | -$211 |